Liquid pharmaceutical composition for the treatment of a posterior eye disease
AssigneeNovaliq GmbH
InventorClive G. WILSON
Life of this patent
Estimating the term…
Abstract
The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
Claims15
A pharmaceutical composition for the treatment of a tissue associated with the posterior segment of an eye of a patient, wherein the composition comprises a non-aqueous, physiologically tolerable, liquid vehicle having a density of at least 1.2 g/ml, and wherein the treatment comprises topical administration to the surface of the eye and/or periocular injection.
The pharmaceutical composition of any preceding claim, wherein the liquid vehicle is selected from perfluorocarbons, semifluorinated alkanes, polysiloxanes, and mixtures thereof.
The pharmaceutical composition of any preceding claim, wherein the liquid vehicle has a density of at least about 1.35 g/ml.
The pharmaceutical composition of any preceding claim, wherein the liquid vehicle has a boiling point of at least about 120° C.
The pharmaceutical composition of any preceding claim, having a dynamic viscosity of not more than about 5 mPas.
The pharmaceutical composition of any preceding claim, wherein the liquid vehicle has a refractive index in the range from 1.29 to 1.35 at 20° C.
The pharmaceutical composition of any preceding claim, comprising an active pharmaceutical ingredient in dissolved or dispersed form, which active ingredient is optionally selected from latanoprost, bimatoprost, tafluprost, travoprost, unoprostone, triamcinolone, dexamethasone, fluorometholone, hydrocortisone, prednisolone, rimexolone, aureomycin, azithromycin, gentamycin, ciprofloxacin, ofloxacin, fusidic acid, kanamycin, levofloxacin, lomefloxacin, oxytetracyclin, tobramycin, natamycin, gentamycin, moxifloxacin, carteolol, timolol, metipranolol, betaxolol, pindolol, levobunolol, brimonidine, clonidine, dipivefrine, apraclonidine, carbachol, pilocarpine, brinzolamide, dorzolamide, aciclovir, trifluridine, ganciclovir, diclofenac, bromfenac, ketorolac, flurbiprofen, and indometacin, including any salts and solvates thereof.
The pharmaceutical composition of any preceding claim, further comprising one or more excipients selected from co-solvents, surfactants, stabilisers, antioxidants, preservatives, and colouring agents.
The pharmaceutical composition of any preceding claim, being formulated so as to provide for the sustained release of the active ingredient over a period of at least about 24 hours.
A method for treating a disease or condition of a tissue associated with the posterior segment of an eye of a patient, comprising (a) administering a pharmaceutical composition comprising a non-aqueous, physiologically tolerable, liquid vehicle having a density of at least 1.2 g/ml by topical administration to the surface of the eye and/or periocular injection, and subsequently (b) bringing the patient into a supine position facing upwards for a sufficiently long time period to allow the composition to migrate from the site of administration to a site in the posterior segment of the eye.
Dependencies are inferred from the claim text.